Hung Trinh, Senior VP of Operations at Seneca Therapeutics and CMC/MFG Consultant and Managing Director at Vertex Biopharm Consulting, shared a post on LinkedIn:
“Targeting Claudin18.2 for cancer theranostics: From molecular imaging to precision therapy
Claudin18.2 as a cancer therapeutic target
CLDN18.2 has emerged as a promising therapeutic target in digestive system cancers, drawing growing interest in the field of precision oncology. Current investigational CLDN18.2-targeted agents include monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T (CAR-T) cell therapies. This section provides an overview of the key concepts and recent advancements in these therapeutic strategies.
Claudin18.2 (CLDN18.2), a specific tight junction protein isoform, is minimally expressed in normal gastric mucosa but aberrantly overexpressed in various cancers. It plays a key role in regulating tumor cell differentiation, proliferation, and migration, making it an attractive therapeutic target, especially in gastric cancer.
Moreover, molecular imaging techniques such as immuno-positron emission tomography, immuno-single photon emission computed tomography, and near-infrared fluorescence imaging enable non-invasive evaluation of CLDN18.2 expression, improving diagnosis and guiding personalized treatment.
This review summarizes recent advances in CLDN18.2-targeted therapies and molecular imaging for cancer management. We outline the biomarker’s biological functions and signaling pathways across cancers, highlighting the development of precision therapeutics.
We also discuss applications and limitations of CLDN18.2-targeted theranostics in digestive malignancies and address clinical translation challenges and future directions.”
Title: Targeting Claudin18.2 for cancer theranostics: From molecular imaging to precision therapy
Authors: Yongshun Liu, Wenpeng Huang, Jessica Hsu, Zhaonan Sun, Weibo Cai, Lei Kang
Other articles featuring Hung Trinh on OncoDaily.